Karyopharm Therapeutics (KPTI) Misses Q1 EPS by 1c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 EPS of ($0.74), $0.01 worse than the analyst estimate of ($0.73).

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• JPMorgan Upgrades Lithium Americas Corp. (LAC:CN) (LAC) to Overweight
• Casey's General Stores (CASY) Tops Q1 EPS by 69c